Recent Study Shows Hydroxychloroquine Doesn't Prevent COVID-19
A new large study shows that the antimalaria drug hydroxychloroquine wasn't able to effectively block the contraction of COVID-19 after exposure, according to the Wall Street Journal.
The 821-person study was published on Wednesday in the New England Journal of Medicine. 12 percent of individuals given the pills tested positive for the virus compared to 14 percent of people given a placebo. Researchers did not detect any major issues with taking the drug. David Boulware, an infectious-diseases specialist at the University of Minnesota stated that public-health authorities shouldn't endorse the drug to individuals exposed to the virus. Researchers are still conducting tests to determine if it would be effective before exposure.
Hydroxychloroquine is used to treat malaria, lupus, and rheumatoid arthritis. The FDA approved the drug for emergencies in March but later issued a warning to only use the drugs in clinical trials and on hospitalized patients. President Trump recently announced that he was taking the drug.
Subjects in the study randomly received either a placebo or 800 mg of hydroxychloroquine, followed by 600 mg six to eight hours later, then 600 mg daily for four more days. Researchers monitored the subjects by routinely testing them or checking for symptoms. Out of the 49 study subjects who took hydroxychloroquine and became sick, 44 percent of them were symptomatic, compared to less than 25 percent of the 58 patients who were given the placebo and became sick.